The implementation and side effect management of immune checkpoint inhibitors in gynecologic oncology: a JAGO/NOGGO survey
Abstract Background The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management...
Saved in:
Main Authors: | Maximilian Riedel, Helene Herrmann, Thomas Bartl, Anna-Maria Rossner, Anna Tatzber, Chiara Flethe, Dario Zocholl, Barbara Schmalfeldt, Jalid Sehouli, Klaus Pietzner |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-025-13432-5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mutation of isocitrate dehydrogenase indicates favorable outcomes in pan-cancer immune checkpoint blockade
by: Zhiyang Huang, et al.
Published: (2025-02-01) -
Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade
by: Victoria E. Stefan, et al.
Published: (2024-11-01) -
Sequentially Activated Smart DNA Nanospheres for Photoimmunotherapy and Immune Checkpoint Blockade
by: Yu Chen, et al.
Published: (2025-01-01) -
Novaks Textbook of Gynecology /
by: Novak,Edmund R
Published: (1961) -
Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade
by: Cheng Xu, et al.
Published: (2023-04-01)